1 IRB review and assessment of risks / benefits Bernard Lo, M.D. July 31, 2008.
-
Upload
pamela-harrison -
Category
Documents
-
view
217 -
download
0
Transcript of 1 IRB review and assessment of risks / benefits Bernard Lo, M.D. July 31, 2008.
1
IRB review andassessment of risks / benefits
Bernard Lo, M.D.
July 31, 2008
2
Why do we have IRBs?
Why do we have federal research
regulations?
3
Nazi “experiments”
1. Unacceptable risk
2. No consent
3. Use of vulnerable subjects
4
Tuskegee study
1932 Study started
1936 Journal told that local MDs asked
not to treat subjects
1940 Subjects not treated in military
1947 USPHS Rapid Treatment Centers
5
Tuskegee study
1968 Whistleblower Peter Buxtun
1969 CDC local chapters of AMA and
NMA reaffirm support,
1970 News coverage
6
Tuskegee study
1974 DHEW issues regulations on
funded research
1974 Tuskegee Benefit Program
7
Fundamental tension in research
Primary goal is generalizable
knowledge, benefit to society
Participants face risks but benefit to
others
8
Ethical violations in Tuskegee
1. Inappropriate risk / benefit ratio
2. Lack of informed and voluntary
consent
3. Targeting of vulnerable population
9
Regulations respond to Tuskegee
1. Beneficence Risks must be acceptable Risks must be minimized
2. Respect for persons Informed and voluntary consent
10
Regulations respond to Tuskegee
3. Justice Equitable selection of subjects Protections for vulnerable subjects
11
Federal requirements for research
Review by IRB Independent of investigators
Risks / benefits acceptable Risks must be minimized
• Must understand science
Include psychosocial risks• Confidentiality
12
Federal requirements for research
Informed and voluntary consent Concerns about undue inducement if
payment Exceptions to consent
• Not capable of consent (children, adults who lack decision-making capacity)
• Impracticable to obtain consent
13
Study 1: epidemiology of hepatitis C
Prospective cohort study of incidence
of hepatitis C and risk factors Blood draws Questionnaires
14
Study 1: epidemiology of hepatitis C
Target population? Injection drug users Commercial sex workers
Vulnerable populations at higher risk
need special protection
15
Study 1: epidemiology of hepatitis C
Medical risks minimal
Physical risks of questionnaires tiny
Psychosocial risks considerable Highly sensitive data
• Alcohol and substance abuse• Sexual behaviors, STDs, HIV• Illegal activities: sex for $, IDU• (Psychiatric illness)
16
Study 1: epidemiology of hepatitis C
If confidentiality breached Legal risk: illegal activities Social harm: stigma, disruption of
relationships Economic harm: loss of employment
17
Study 1: epidemiology of hepatitis C
How to minimize risks? Staff training Use coded or de-identified data Data security
18
Study 1: epidemiology of hepatitis C
How to minimize risks? Data security
• Do not store identified data on laptops, removable devices
• Encryption Certificate of confidentiality
Inform participants of risk during
consent process
19
Study 1: epidemiology of hepatitis C
Cannot guarantee absolute
confidentiality Reporting of communicable diseases Audits by funders
20
21
Study 2: cholesterol-lowering drug
Phase II RCT to study whether new
drug to lower LDL prevents
progression of coronary disease Compare to standard statin Known to lower LDL more than statins
22
Study 2: cholesterol-lowering drug
Primary endpoint is progression of
CAD on follow-up angiography
compared to baseline angiography
Secondary endpoints Combined cardiac death + MI Ischemia on exercise nuclear imaging
23
Study 2: context
Drug already approved by FDA on
basis of LDL reduction
Is advantage in vascular progression a
surrogate endpoint? More power to detect surrogate endpoint
than clinical endpoint
24
Question for audience
Would repeat angiography be indicated
in clinical care after starting patient on
lipid-lowering drug?
25
Question for audience
Conceivable that detect L main
stenosis?
26
Question for audience
Do you regard benefit / risk balance as
acceptable?
27
Study 2: What are benefits of study?
Direct benefits intended by study
design Drug to lower LDL, monitoring of LDL ? Angiography
28
Study 2: What are benefits of study?
Collateral benefits of being in study,
independent of research intervention Education about CAD risk Attention of staff Payment for participation
• May not be considered by IRB as benefit
29
Study 2: What are risks of study?
Procedures that offer prospect direct
benefit Adverse effects of study drug
Procedures to answer research
question Risks of angiography
30
Questions regarding Study 2
May invasive procedures not indicated
in clinical care be allowed in research?
How can risks and benefits of complex
study be combined into overall
assessment?
31
For interventions that offer prospect of direct benefit
Greater level of risk acceptable than for
interventions solely for research
Balance of benefits / burdens should
be comparable to standard care
32
For interventions that offer no prospect of direct benefit
May not justify by benefits of study
drug Study drug might reduce cardiac events
• May not justify by collateral benefits
33
For interventions that offer no prospect of direct benefit
Risks must be reasonable compared to
potential knowledge gained
Risks must be minimized consistent
with valid research design
34
In Study 2
Are risks minimized? Noninvasive means to assess progression of
vascular occlusion• CT angiography
• Doppler studies of carotid arteries
35
In Study 2
What is potential knowledge gained? Is greater reduction in LDL clinically
meaningful?• What will this study add to what is already
known?
36
Question for audience
Do you regard benefit / risk balance as
acceptable?
37
Outcome of Study 2
Endpoint was progression of carotid
disease evaluated by Doppler
Study was negative study Was short-term benefit realistic?
38
39
Looking ahead
When is IRB review not necessary? Not research Certain survey, interview research Certain research with existing data and
biological specimens
40
Looking ahead
When may IRB review be expedited? Minimal risk in technical sense On list approved by DHHS
• Venipuncture
• Noninvasive• Not XRs
• Minor changes
• Continuing review
41
Practical IRB tips on 8/14
Bring your questions!